Possibilities of nicorandil for coronary insufficiency correction in patients with ischemic heart disease and diabetes mellitus type 2

Cardiovascular complications of type 2 diabetes mellitus (T2DM) are now a global health problem, due to their main cause of mortality of these patients. Ischemic heart disease (IHD) among all cardiovascular diseases occupies a leading position. The purpose of the study was comparative assessment of possibilities of coronary reserve correction in patients with stable angina and T2DM by nitrates and activator of potassium channels by nicorandil. The study included 54 patients with stable angina of 2-3 functional classes (FC) and T2DM. The dynamics of frequency of angina attacks, mean FC of angina pectoris, exercise tolerance, vasoregulatory function of endothelium under the influence of therapy with nicorandil, isosorbide dinitrate (ISDN) and isosorbide-5-Mononitrate (I5MN) were analyzed. In patients with IHD and T2DM drug of choice for long-term treatment is nicorandil with greater antianginal and anti-ischemic efficacy compared with traditional nitrates. Nicorandil effectively corrects endothelial dysfunction, without causing the development of tolerance and without reducing its effectiveness while taking hypoglycemic therapy.

1. Dedov I.I. Algorithms for specialized medical care for patients with diabetes. Under the editorship of I.I. Dedova, M.V. Shestakova, A.Yu. Mayorov. Sakharny Diabet. 2017; 20 (1S): 1-112. (In Russ).

2. Bulakhova E.Yu., Korennova O.Yu., Kondrasheva M.N., Kamionko O.A., Stupakova T.F. Clinical benefits of nicorandil therapy compared with isosorbide-5-mononitrate in IHD patients. Serdtse. 2013; 2 (12): 83-87. (In Russ).

3. Ryabikhin E.A., Mozheiko M.E., Krasilnikova Yu.A. Efficacy and safety of longterm nicorandil therapy in patients with stable angina pectoris. Serdtse. 2014; 13 (3): 151– 155. (In Russ).

4. Jiang J., Li Y., Zhou Y., et al. Oral nicorandil reduces ischemic attacks in patients with stable angina: A prospective, multicenter, openlabel, randomized, controlled study. Int J Cardiol. 2016; 224: 183-7.

5. Voronina V.P., Martsevich S.Yu., Kutishenko N.P. et al. Assessment of the antiischemic and antianginal effects of nicorandil using stress tests on treadmill in the framework of the KVAZAR study. Rossiyskiy Kardiologichesky Zhurnal. 2017; 2: 91-7. (In Russ).

6. Ametov A.C., Orlov V.A. Features of painless myocardial ischemia in patients with insulin-dependent diabetes mellitus. Problemy Endokrinologii. 2007; 5: 19–22. (In Russ).

7. Aleksandrov A.A., Bondarenko I.Z., Kukharenko S.S., Yadrikhinskaya M.N. Diabetes and coronary heart disease: the search for a solution. Sakharny Diabet. 2005; 3: 34-38. (In Russ).

8. Dzugkoev S.G., Mozhaeva I.V., Takoyeva E.A., Dzugkoeva F.S., Margieva O.I. Mechanisms of endothelial dysfunction and prospects for correction. Fundamentalnye Issledovaniya. 2014; 4-1: 198- 204. (In Russ).

9. Melnikova, Yu.S., Makarova, T.P. Endothelial dysfunction as a central component of the pathogenesis of chronic diseases. Kazansky Meditsinsky Zhurnal. 2015; 96 (4): 659-665. (In Russ).

10. Karasu C. Glycoxidative stress and cardiovascular complications in experimentally-induced diabetes: effects of antioxidant treatment. Open Cardiovasc. Med. J. 2010; 4: 240–256.

11. Chrissobolis S. Oxidative stress and endothelial dysfunction in cerebrovascular disease. Front. Biosci. 2011; 16(1): 1733–1745.

12. Mkrtumyan A.M. Glycemia as a risk factor for cardiovascular diseases. Diabetes. 2010; 3: 80-82 (In Russ).

13. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. N. Engl. J. Med. 2008; 359: 1577–89.

14. Pashentseva A.V., Verbovoy A.F. Sugar-lowering therapy and cardiovascular safety. Pharmateka. 2015; 13: 32–37. (In Russ).

15. Sharonova L.A., Verbovoy A.F., Kosareva O.V. The role of sulfonylurea drugs in the treatment of type 2 diabetes. Meditsinsky Sovet. 2016; 3: 6–9. (In Russ).

16. Vatutin N.T., Kalinkina N.V., Kolesnikov V.S., Shevelik A.N. The phenomenon of preconditioning. Serdtse. 2013; 12 (4): 199–206. (In Russ).

17. Baxter G.F. Role of adenosine in delayed preconditioning of myocardium. Cardiovasc Re. 2002; 55: 483–494.

18. Lee T.M., Chou T.F. Impairment of myocardial protection in type 2 diabetic patients. J. Clin Endocrinol Metab. 2003; 88: 531-537.

19. Strojek K., Yoon K.H., Hruba V. et al. Effect of dapagliflozin in patients with type 2 diabetes who have in adequate glycaemic control with glimepiride: a randomized, 24-week, doubleblind, placebo-controlled trial. Diabetes, Obesity and Metabolism. 2011; 13: 10.